Calvin Pan now presents on maternal TDF for prevention of vertical transmission in highly viraemic mothers #TLM22 clinicaltrials.gov/ct2/show/NCT03…
280 HBeAg+ mothers gestational age 12-13 weeks randomised 1:1 to early TDF from GW 14, or control group of TDF at GW 28. All infants got active immunoprophylaxis and HBIg only given to infants in the control group; 1ry endpoint HBV transmission at 28 weeks #TLM22
Women in experimental arm had lower HBV DNA at delivery; there was no transmission of HBV to infants in either group. A sensitivity analysis suggested a conservative 2% infection rate in experimental arm. Safety similar, but small numbers #TLM22
Might represent a simplified early tx approach for reducing MTCT in areas with limited HBIg access #TLM22
• • •
Missing some Tweet in this thread? You can try to
force a refresh
